Review of hepatitis B therapeutics.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20954965.
- Also identified by DOI 10.1086/656624 and PMC identifier 2977969.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Currently, there are 7 approved therapies for chronic hepatitis B virus (HBV) infection, an increase from just 3 agents 5 years ago. This review will focus on the pharmacology, potency, and adverse events associated with immunomodulatory agents and nucleos(t)ide analogues, with an emphasis on targets of therapy within the HBV life cycle. We will also offer guidelines for the use of available anti-HBV agents and review the emerging challenges in hepatitis B management, including HBV drug resistance, its management, and the potential role of combination therapy.
Medical subject headings
- Antiviral Agents
- Hepatitis B